Ono Pharmaceutical

📖 Wiki Page

company698 wordssynced 2026-04-02

Ono Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan, with a focus on oncology, immunology, and neuroscience research and development. Founded in 1919, Ono has become one of Japan's leading innovative pharmaceutical companies.

Overview

flowchart TD companies_ono_pharmaceutical["Ono Pharmaceutical"] style companies_ono_pharmaceutical fill:#4fc3f7,stroke:#333,color:#000 companies_ono_pharma_0["Funding"] companies_ono_pharmaceutical -->|"includes"| companies_ono_pharma_0 style companies_ono_pharma_0 fill:#81c784,stroke:#333,color:#000 companies_ono_pharma_1["Corporate Highlights"] companies_ono_pharmaceutical -->|"includes"| companies_ono_pharma_1 style companies_ono_pharma_1 fill:#ef5350,stroke:#333,color:#000 companies_ono_pharma_2["History and Development"] companies_ono_pharmaceutical -->|"includes"| companies_ono_pharma_2 style companies_ono_pharma_2 fill:#ffd54f,stroke:#333,color:#000 companies_ono_pharma_3["Founded 1919"] companies_ono_pharmaceutical -->|"includes"| companies_ono_pharma_3 style companies_ono_pharma_3 fill:#ce93d8,stroke:#333,color:#000 companies_ono_pharma_4["Expansion 1950s-1990s"] companies_ono_pharmaceutical -->|"includes"| companies_ono_pharma_4 style companies_ono_pharma_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ono_pharma_5["Innovation Era 2000s-Present"] companies_ono_pharmaceutical -->|"includes"| companies_ono_pharma_5 style companies_ono_pharma_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Ono Pharmaceutical has evolved into a major Japanese drug developer with significant partnerships with global pharmaceutical companies. The company operates research facilities in Japan and maintains collaborations with leading academic institutions worldwide["@onoa"].

Funding

IPO: 1950s (TSE: 4568)
Market Cap: ~$15B (2026)

Corporate Highlights

Founded: 1919
Headquarters: Osaka, Japan
Employees: Approximately 6,000
TSE: 4568
Market Cap: Approximately $15 billion USD

History and Development

Founded (1919)

Ono was founded in 1919 as a small pharmacy in Osaka, originally focusing on manufacturing and selling pharmaceutical products.

Expansion (1950s-1990s)

Expanded into prescription pharmaceuticals
Established research laboratories
Developed strong cardiovascular and gastrointestinal portfolios

Innovation Era (2000s-Present)

Focused on innovative drug development
Built strong oncology pipeline
Established global partnerships
Developed Opdivo (nivolumab), one of the world's first PD-1 inhibitors

Key Partnerships

Bristol-Myers Squibb (BMS)

Ono and BMS have a significant partnership centered on Opdivo (nivolumab):

Ono discovered nivolumab and retained rights in Japan, Korea, and Taiwan
BMS acquired global rights outside these territories
The partnership has expanded to include multiple combination therapies
Opdivo is one of the world's best-selling cancer drugs[@opdivo2016]

Pfizer

Co-development of oncology candidates
Combination therapy development
Global clinical trial collaboration

AstraZeneca

Cardiovascular and metabolic diseases collaboration
Research partnerships in inflammation

Pipeline and Programs

Neuroscience Programs

| Drug Candidate | Target | Indication | Stage |
|---------------|--------|------------|-------|
| ONO-4474 | TREM2](/proteins/trem2) | Alzheimer's disease | Phase 1 |
| ONO-4686 | Tau | Alzheimer's disease | Preclinical |
| ONO-8809 | Undisclosed | CNS disorders | Phase 1 |
| ONO-2910 | Undisclosed | Migraine | Phase 2 |

Oncology Programs (Key)

| Drug Candidate | Target | Indication | Stage |
|---------------|--------|------------|-------|
| Opdivo (Nivolumab) | PD-1 | Multiple cancers | Approved |
| Yervoy (Ipilimumab) | CTLA-4 | Melanoma, others | Approved |
| ONO-4538 | PD-1 | Various tumors | Approved |
| ONO-7914 | LAG-3 | Solid tumors | Phase 1 |

Neurological Relevance

Ono's neuroscience pipeline includes significant programs for neurodegenerative diseases[@onob]:

TREM2 Antibodies (ONO-4474)

ONO-4474 represents a novel approach targeting microglia:

TREM2 is expressed on microglia in the brain
Genetic variants increase Alzheimer's disease risk
Antibodies may enhance microglia function and clear amyloid
Phase 1 trials evaluating safety and pharmacokinetics

Tau Targeting (ONO-4686)

ONO-4686 targets tau protein pathology:

Anti-tau antibodies may block tau spread between neurons
Complements amyloid-targeted approaches
Addresses neurofibrillary tangles
Preclinical development ongoing

BACE Inhibitors (Discontinued)

The company previously developed BACE1 inhibitors for Alzheimer's disease:

ONO-4485 reached Phase 2 development
Discontinued in 2018 due to liver toxicity in clinical trials
Reflects challenges in Alzheimer's drug development - safety concerns with BACE inhibition[@bace]

Research Focus Areas

[Neuroinflammation](/mechanisms/neuroinflammation) in neurodegeneration
[Microglia](/cell-types/microglia) biology and modulation
Blood-brain barrier penetration strategies
Novel antibody engineering for CNS delivery

Science and Technology

Antibody Engineering

Ono has built expertise in therapeutic antibody development:

Monoclonal antibody discovery
Antibody humanization
Bispecific antibody platforms
Antibody-drug conjugates

Immunology Focus

Checkpoint inhibitors (PD-1, CTLA-4, LAG-3)
Immuno-oncology combinations
Cytokine modulators

Financial Highlights (2024)

Revenue: Approximately $3.5 billion USD (500 billion JPY)
R&D Investment: Approximately $800 million USD (120 billion JPY)
Market Cap: Approximately $15 billion USD (2 trillion JPY)
Opdivo Royalty Income: Significant contributor to revenue

Global Presence

Japan: Headquarters and primary market
US: Clinical development operations
Europe: Research partnerships
Asia: Regional partnerships in Korea and Taiwan
[Alzheimer's Disease](/diseases/alzheimers-disease)
[TREM2](/proteins/trem2-protein)](/mechanisms/trem2)
[Tau Protein](/proteins/tau)
[Microglia](/cell-types/microglia)
[Bristol-Myers Squibb](/companies/bristol-myers)
Opdivo
[Neuroinflammation](/mechanisms/neuroinflammation)
[PD-1 Signaling](/genes/gnal)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/genes/ar)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Ono Pharmaceutical, Company Website (n.d.)

Ono Corporate Overview, Annual Report (n.d.)

Ono Neuroscience Pipeline, R&D Presentation (n.d.)

[Opdivo Development, Nature Reviews Drug Discovery (2016)](https://doi.org/10.1038/nrd.2016.136)

[BACE Inhibitor Challenges, Alzheimer's & Dementia (n.d.)](https://doi.org/10.1012/alz.12095)

📖 View canonical wiki page →